TY - T1 - Oncolytic adenovirus drives specific immune response generated by a poly-epitope pDNA vaccine encoding melanoma neoantigens into the tumor site SN - / UR - http://hdl.handle.net/10138/306973 T3 - A1 - Lopes, Alessandra; Feola, Sara; Ligot, Sophie; Fusciello, Manlio; Vandermeulen, Gaëlle; Préat, Véronique; Cerullo, Vincenzo A2 - PB - Y1 - 2019 LA - eng AB - Background: DNA vaccines against cancer held great promises due to the generation of a specific and long lasting immune response. However, when used as a single therapy, they are not able to drive the generated immune response into the tumor, because of the immunosuppressive microenvironment, thus limiting their use in humans. To enhance DNA vaccine efficacy, we combined a new poly-epitope DNA vaccine encoding melanoma tumor associated antigens and B16F1-specific neoantigens with an oncolytic vi... VO - IS - SP - OP - KW - ACTIVATION; CANCER; Cancer; DNA vaccine; EFFICACY; IDENTIFICATION; INTERLEUKIN-2; Melanoma neoantigens; NATURAL-KILLER-CELLS; NK CELLS; Oncolytic adenovirus; RECEPTOR; RECRUITMENT; THERAPY; Tumor microenvironment; 3122 Cancers N1 - PP - ER -